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Abstract
Monocyte activation and polarization play essential roles in many chronic inflammatory
diseases. An imbalance of M1 and M2 macrophage activation (pro-inflammatory and alter-
natively activated, respectively) is believed to be a key aspect in the etiology of these dis-
eases, thus a therapeutic approach that regulates macrophage activation could be of broad
clinical relevance. Methylglyoxal-bis-guanylhydrazone (MGBG), a regulator of polyamine
metabolism, has recently been shown to be concentrated in monocytes and macrophages,
and interfere with HIV integration into the DNA of these cells in vitro. RNA expression analy-
sis of monocytes from HIV+ and control donors with or without MGBG treatment revealed
the only gene to be consistently down regulated by MGBG to be osteopontin (OPN). The
elevated expression of this pro-inflammatory cytokine and monocyte chemoattractant is
associated with various chronic inflammatory diseases. We demonstrate that MGBG is a
potent inhibitor of secreted OPN (sOPN) in cultured monocytes with 50% inhibition achieved
at 0.1 μM of the drug. Furthermore, inhibition of OPN RNA transcription in monocyte cul-
tures occurs at similar concentrations of the drug. During differentiation of monocytes into
macrophages in vitro, monocytes express cell surface CD16 and the cells undergo limited
DNA synthesis as measured by uptake of BrdU. MGBG inhibited both activities at similar
doses to those regulating OPN expression. In addition, monocyte treatment with MGBG
inhibited differentiation into both M1 and M2 classes of macrophages at non-toxic doses.
The inhibition of differentiation and anti-OPN effects of MGBG were specific for monocytes
in that differentiated macrophages were nearly resistant to MGBG activities. Thus MGBG
may have potential therapeutic utility in reducing or normalizing OPN levels and regulating
monocyte activation in diseases that involve chronic inflammation.
Introduction
Monocyte-derived macrophages can be classified as pro-inflammatory classical M1 or anti-
inflammatory alternatively activated M2 macrophages in response to different stimuli [1, 2].
T-helper 1 (Th1) cytokine induced M1 macrophages release high levels of pro-inflammatory
cytokines and are involved in microorganism and cell killing; while T-helper 2 (Th2) cytokine
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induced M2 macrophages are involved in phagocytosis of apoptotic cells, tissue remodeling,
angiogenesis, and wound repair [2–4]. M1 and M2 macrophages are further classified into sev-
eral subtypes with distinct differentiation markers [4]. The accumulated evidence indicates
that an imbalance of macrophage polarization or activation is associated with chronic inflam-
matory diseases including rheumatoid arthritis, atherosclerosis, cancer, obesity, diabetes, and
various neurodegenerative conditions such as macular degeneration and HIV-associated
dementia (HAD) [5–7]. Controlling monocyte activation and trafficking might provide a sig-
nificant therapeutic route for treatment of these chronic diseases.
Monocytes are an essential component of the innate immune system and are critically
involved in the initiation of an adaptive immune response. Human peripheral blood mono-
cytes can be broadly classified into two groups dependent on their level of expression of the
low-affinity Fc receptor CD16 [8–11]. The majority of human monocytes (~ 80%) express little
or no CD16 and high levels of the chemokine receptor 2 (CCR2). These “classical” monocytes
migrate in response to monocyte chemoattractant protein 1 (MCP1 also designated CCL2)
and can be induced to differentiate into tissue macrophages or dendritic cells in vitro if pro-
vided a suitable surface for attachment in concert with exposure to the macrophage colony
stimulating factor (M-CSF) or other factors [11–13]. The remaining 10–20% of human blood
monocytes express high levels of CD16 and little or no CCR2. These cells have been demon-
strated to migrate in response to fractalkine (CXCL3) [14]. Early studies have shown that
CD16 expression is up-regulated by culturing human monocytes, and that CD14+CD16+
monocytes may be derived from the CD14+/CD16- fraction [15, 16]. CD14+CD16+ mono-
cytes exhibit features of tissue macrophages, and have been labeled as pro-inflammatory based
on their high level production of the pro-inflammatory cytokine tumor necrosis factor (TNF)
and low levels of the anti-inflammatory cytokine interleukin 10 (IL10) [9, 17–19]. Increased
numbers of blood CD14+CD16+ monocytes are observed in a number of viral and autoim-
mune disorders including rheumatoid arthritis, HAD, amyotrophic lateral sclerosis (ALS),
Alzheimer’s disease, and some malignancies [20–25]. Furthermore, there is increasing evi-
dence suggesting that CD14+CD16+ monocytes may serve as HIV reservoirs in AIDS patients,
promoting ongoing HIV infection [23, 26, 27]. For all these reasons, the in vitro and in vivo
properties and function of these CD14+CD16+ monocytes are of considerable interest.
In studies on the relationship of macrophage activation to chronic disease, attention has
been drawn to OPN as a critical cofactor. OPN is an extracellular matrix glycoprotein that
influences multiple physiological functions in vivo, including bone metabolism, immune regu-
lation, wound healing, cell survival and tumor progression [28–31]. Accumulating evidence
indicates that OPN is a pro-inflammatory cytokine broadly involved in chronic inflammatory
diseases, obesity, diabetes, autoimmune diseases, and neurodegenerative disorders [32, 33].
OPN is expressed in many cell types and tissues including activated macrophages and T cells
[32]. Various OPN isoforms have been identified, and are apparently the result of alternative
splicing, alternative translation, and post translational modifications [34]. In addition to
secreted forms of OPN, intracellular OPN (iOPN) is found in the cytoplasm and the nucleus
and has functions distinct from secreted OPN (sOPN) [35]. High levels of OPN expression in
tissue and blood have been reported in patients with cancer [36, 37], infectious diseases such
as HAD [38, 39], autoimmune disorders including multiple sclerosis and rheumatoid arthritis
[40–42], obesity and diabetes [43, 44]. Studies of elevated OPN levels in inflammatory wounds
reveal that OPN functions as an inflammation mediator and macrophage functional regulator
[30, 31]. OPN exhibits Th1 cytokine functions in cell-mediated immunity assays [45]. Thera-
peutic approaches utilizing OPN small interfering RNA and anti-OPN neutralizing antibodies
have been employed in cancer and inflammatory diseases [46–50] and have demonstrated the
potential importance of OPN regulation as a therapeutic target.
MGBG regulates OPN expression in monocytes
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Polyamines are required for cell differentiation and proliferation in general [51, 52]. Inhibi-
tors of polyamine biosynthesis interfere with TNF-induced macrophage activation [53, 54],
and therefore are thought to have potential value in controlling pathological inflammation
associated with activated macrophages. MGBG, a polyamine biosynthesis inhibitor, is known
to interfere with polyamine biosynthesis via the inhibition of the enzyme s-adenosylmethio-
nine decarboxylase (SAMDC) [55–57]. Our recent studies have shown that MGBG is taken up
specifically by monocytes and macrophages, and it inhibits HIV DNA integration and HIV
expression in macrophages [58]. Gene expression studies performed on both HIV+ and
healthy cultured peripheral blood mononuclear cells (PBMCs) showed that one gene, OPN,
was consistently down regulated after overnight exposure to MGBG [59]. In this study, we
show that MGBG regulates expression of OPN at both RNA and secreted protein levels in
monocytes and also inhibits monocyte differentiation into M1 and M2 macrophage subsets
without apparent effect on mature macrophage OPN expression.
Materials and methods
Cell culture and macrophage polarization
Human buffy coats or heparinized blood were obtained from blood donors from the Stanford
Blood Center. PBMCs were isolated by density gradient centrifugation using Percoll or Ficoll-
Paque Plus (GE Healthcare Life Sciences, Pittsburgh, PA). Monocytes were isolated from
PBMCs using anti-CD14 (Miltenyi Biotech, Auburn, CA) MACS magnetic separation system.
PBMCs or sorted monocytes were cultured in RPMI 1640 containing L-glutamine supple-
mented with 10% fetal bovine serum (FBS) and 1 mM sodium pyruvate. MGBG (Ash Stevens,
Riverview, MI) and spermine (SPM) (Sigma-Aldrich, St. Louis, MO) were added where speci-
fied. FBS was replaced by 5% human serum when SPM was used. 10 ng/ml M-CSF (R&D Sys-
tems, Minneapolis, MN) was supplemented to aid the maturity of macrophages in culture. Cells
were incubated at 1 million cells per ml medium unless otherwise indicated under suspension
culture in 50 ml conical polypropylene tubes or 5 ml BD Falcon polypropylene tubes at 37˚C in
a humidified 5% CO2 incubator. After incubating for a designated number of days, cells were
collected for flow cytometry and total RNA preparation, and culture supernatants were saved
for cytokine measurement using enzyme-linked immunosorbent assay (ELISA). To induce
monocytes into M1 or M2 macrophages, isolated monocytes were incubated with 50 ng/ml
interferon γ (INF-γ) and 1 μg/ml liposaccharides (LPS) or 50 ng/ml interleukin 4 (IL4) (Sigma-
Aldrich, St. Louis, MO), respectively, for 5 to 6 days for differentiation and polarization.
Quantitative real-time PCR analysis
Cultured monocytes were spun down and lysed in Trizol reagents (Thermo Scientific, Wal-
tham, MA), and total RNA prepared using the PureLink Micro to Midi total RNA purification
systems (Thermo Scientific, Waltham, MA). 100 ng of total RNA was converted to cDNA
using the Verso cDNA Synthesis kit (Thermo Scientific, Waltham, MA) by incubating at 42˚C
for 1 hour followed by 95˚C for 2 minutes. PCR was performed on the Agilent Mx3000P qPCR
system using ABsolute Blue qPCR SYBR Kit (Thermo Scientific, Waltham, MA) and 200 ng
cDNA in a 25 μl reaction. Thermal amplification profile included one cycle of template dena-
turation at 95˚C for 15 minutes followed by 40 cycles of 95˚C for 15 seconds, 60˚C for 30 sec-
onds, and 72˚C for 30 seconds. The presence of a single amplified product was confirmed by
DNA melting point analysis. Threshold cycles (Ct) for each amplification reaction were deter-
mined using respective software for the instrument. All samples were amplified with the
human β-actin LightCycler—Primer Set (Roche Diagnostics, Indianapolis, IN) and the OPN
primers (Forward: 5’- AGC CAC AAG CAG TCC AGA TTA T and Reverse: 5’- TTG
MGBG regulates OPN expression in monocytes
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ACC TCA GAA GAT GCA CTA TC). Results with the OPN primers for individual samples
were normalized to signals obtained with β-actin from the same sample (Ct actin—Ct OPN).
Gene expression fold change was calculated (2Δ(Ct actin–Ct OPN)).
Flow cytometry analysis
i. Macrophage differentiation study. Monocytes or macrophages were double stained for dif-
ferentiation marker expression. One million freshly isolated or cultured cells were incubated
with 10 μl of peridinin chlorophyll protein (PerCP) conjugated anti-CD14 monoclonal anti-
body (BD Biosciences, San Jose, CA) and fluorescein isothiocyanate (FITC) or phycoery-
thrin (PE) conjugated monoclonal antibodies against macrophage differentiation markers
for 20 minutes at room temperature in 100 μl phosphate buffered saline (PBS). Matching
isotype antibody staining was performed in parallel for cell population gating. After washing
and fixing, fluorescent emission was measured using a BD FACScan flow cytometer (Becton
Dickinson, Franklin Lakes, NJ). 10,000 to 50,000 cells were analyzed per sample. Cell debris
and main subpopulations of the cells were gated using forward and side scatter (FSC and
SSC, respectively) plots. Cells were further gated according to isotype antibody staining (S1
Fig). Geometric mean fluorescence or percentage of the cell population was obtained for the
gated cells.
ii. Intracellular staining of iONP. Macrophage iOPN expression was measured using the
Inside Stain Kit (Miltenyi Biotec, San Diego, CA). Cultured cells were stained with surface
antibodies PerCP-CD14 and FITC-CD16 followed by iOPN staining using the Inside Stain
kit and PE conjugated anti-OPN antibody (BD Biosciences, San Jose, CA) according to
manufacturer’s instructions.
iii. BrdU incorporation study. Monocyte BrdU uptake or DNA synthesis was determined using a
FITC BrdU flow kit (BD Biosciences, San Jose, CA). Sorted monocytes were cultured and
pulsed with 10 μM BrdU for 3–6 days supplemented with 100 ng/ml M-CSF. Cells were also
treated with or without MGBG. After culture, the cells were collected and stained with PerCP
conjugated anti-CD14 antibody. The percentage of BrdU positive cells were measured after
BrdU staining using the FITC BrdU flow kit according to manufacturer’s instructions.
Cytokine assay
Cell culture supernatants were collected for sOPN cytokine measurement. Cytokine levels
were measured using a Human OPN Quantikine ELISA kit (R&D Systems, Minneapolis, MN)
according to manufacturer’s instructions. Each sample was tested in duplicates.
Statistical analysis
A two-tailed paired t-test was used to determine statistical differences, and P < 0.05 was con-
sidered significant (S1 Table). All the experiments were carried out for at least three times
unless otherwise indicated. Data were presented as means and SEM.
Results
MGBG inhibits both OPN RNA expression and secreted protein levels in a
dose-dependent manner in normal monocyte cultures
Previous gene expression screening studies in PBMC preparations from HIV infected and
healthy individuals showed that of the genes affected by MGBG, OPN was the only gene
MGBG regulates OPN expression in monocytes
PLOS ONE | https://doi.org/10.1371/journal.pone.0192680 March 14, 2018 4 / 16
consistently down regulated in all specimens [59]. Considering that monocytes and macro-
phages are the only blood cells capable of taking up significant amounts of MGBG [58] and the
importance of OPN as a macrophage produced factor implicated in the pathogenesis of HIV
disease and the chemotaxis of monocytes into diseased tissues [60–62], most subsequent stud-
ies were carried out in these cell populations and focused on the role that MGBG might play in
regulation of OPN expression.
To further investigate the effects of MGBG on the production of OPN, various doses of the
drug were incubated in cultures of purified monocytes isolated from healthy individuals. Fig 1
shows that OPN RNA and secreted protein (sOPN) but not iOPN levels were significantly
reduced (p< 0.005) by MGBG treatment in a dose-dependent manner in 1 day cultured
monocytes. As in earlier studies of HIV infection, the regulation of OPN expression occurred
at submicromolar levels of MGBG, and there were no observed toxicities at the drug doses
tested. The 50% effective dose (ED50) of MGBG on OPN RNA expression and OPN protein
level after one day of treatment was observed at approximately 0.1 μM. The effect of MGBG on
OPN expression was also related to time of exposure with longer exposures associated with
more profound inhibition of sOPN expression as shown in Fig 2A. In the performance of
monocyte cultures with addition of MGBG at different time points after culture initiation, it
was noted that the OPN regulatory effect was reduced when MGBG was added to monocyte
cultures at later time points. In contrast to the regulation of sOPN by MGBG in monocyte cul-
tures, mature macrophage (after six days of monocyte cultivation) production of sOPN was
not significantly affected even at high concentrations of MGBG (Fig 2B).
Fig 1. MGBG inhibited sOPN levels and gene expression in cultured human monocytes. 1 day cultured monocytes
were collected for total RNA extraction and iOPN expression, and culture supernatants for OPN ELISA; quantitative
real-time PCR was performed for OPN gene expression. iOPN expression was measured by flow cytometry. MGBG
decreased OPN gene expression and sOPN level in a dose-dependent manner. MGBG slightly decreased iOPN
expression. The data were normalized against that of untreated controls. The average sOPN level for 1 day untreated
monocytes was approximately 3 ng/ml. The iOPN geometric mean florescence of 1 day untreated cells varies among
individuals ranging from 209–689. The OPN RNA level was calculated from β-actin normalized Ct difference of 1D
cultured cells versus cells at isolation. The OPN Ct difference of 1 day untreated monocytes also varies among
individuals ranging from 1.7 to 9.9. ED50 of MGBG on OPN cytokine level and gene expression on day 1: ~ 0.1 μM,
n = 4, means and SEM.
https://doi.org/10.1371/journal.pone.0192680.g001
MGBG regulates OPN expression in monocytes
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MGBG regulates activation of cultured monocytes
Monocyte activation in vitro is associated with up-regulation of CD16, a differentiation marker
that is expressed on monocytes trafficking to tissue-based sites of inflammation [9, 17–19].
In vitro activation is also associated with short term uptake of BrdU by monocytes in the
course of this differentiation process [63]. A small fraction (4–5%) of cultured monocytes was
observed taking up BrdU during this process. Fig 3A shows that CD16 expression spontane-
ously increased in cultured monocytes whereas this aspect of cell differentiation was inhibited
Fig 2. MGBG potently inhibited sOPN production in monocytes, but showed limited inhibitory effect in differentiated
macrophages. (A). MGBG significantly inhibited sOPN production in monocytes. The degree of MGBG inhibition on sOPN was
related to time of exposure. Isolated human monocytes were cultured at 0.1 million cells per ml with various concentrations of
MGBG for 16 hr, 1, 2 and 3 days. MGBG showed potent inhibition on monocyte sOPN production with IC50< 0.1 μM on day 3.
Data were presented as percentage of untreated controls. The average sOPN levels of untreated monocytes were approximately 110,
130, 670 and 5300 pg/ml at 16 hr, 1, 2, and 3 days, respectively. The inhibition is independent of cytotoxicity (e.g. little cell death at
16 hours and day 1). The data is normalized to number of live cells in the culture. n = 2. (B). MGBG showed limited inhibitory effect
on sOPN production in mature macrophages. Isolated monocytes were cultured to allowed to differentiate into macrophages for 6
days prior to drug treatment. Fresh media was replaced and cells were treated with 10 μM MGBG for 3 days. n = 4, means and SEM.
https://doi.org/10.1371/journal.pone.0192680.g002
Fig 3. MGBG inhibited monocyte CD16 expression and BrdU incorporation. Isolated human monocytes were cultured in suspension with or without
MGBG treatment. CD16 expression was measured by flow cytometry. (A). Monocytes differentiate spontaneously in culture. CD16 expression level
increases in monocyte culture. n = 4, means and SEM. (B). MGBG inhibited CD16 expression in 1 day cultured monocytes in a dose-dependent manner.
The average CD16 geometric mean fluorescence of 1 day untreated monocytes was measured at 108 units. n = 4, means and SEM. (C). MGBG inhibited
BrdU incorporation in cultured monocytes. Isolated human monocytes were cultured for 3–6 days for BrdU incorporation using a FITC BrdU flow kit.
The average percentage of BrdU incorporated untreated monocytes was measured at 4.7%. MGBG inhibited monocyte BrdU uptake in a dose-dependent
manner. n = 5, means and SEM.
https://doi.org/10.1371/journal.pone.0192680.g003
MGBG regulates OPN expression in monocytes
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in a dose-dependent manner in cultures exposed to MGBG (Fig 3B). In parallel experiments,
BrdU uptake in monocytes was similarly inhibited by MGBG in 3–6 day monocyte cultures
(Fig 3C). In contrast, OPN expression in macrophages was relatively unaffected by MGBG
(Fig 2B). When monocyte cultures were allowed to differentiate into macrophages in vitro, a
time dependent decrease in regulation of CD16 expression by MGBG was observed: 6 day old
macrophages were relatively unaffected by MGBG (Fig 4). Both the regulation of OPN and
CD16 expression by MGBG were progressively reversed by exogenous addition of increasing
amount of SPM, consistent with the regulation being mediated by MGBG uptake through the
polyamine transporter (Fig 5).
MGBG treatment interferes with induction of monocytes into polarized
macrophages
Monocyte activation leads to two functional forms of macrophages: those involved in inflam-
mation termed M1 and those more associated with suppressive or M2 functions. To test
whether MGBG would preferentially regulate or affect monocyte activation/differentiation
into one of these macrophage subsets, monocytes were cultured in media that promoted either
M1 or M2 macrophage differentiation with or without 0.4 μM MGBG treatment for 5–6 days.
The culture conditions induced characteristic changes consistent with macrophage polariza-
tion. INF-γ and LPS induced M1 macrophages appeared elongated whereas IL4 induced M2
macrophages appeared more rounded compared to non-induced controls. Fig 6 shows the
effects of MGBG on macrophage differentiation markers in polarized macrophages. In each
panel, expression of monocyte antigens or baseline differentiation markers, non-polarized
control macrophages, M1 or M2 polarized macrophages with or without drug treatment are
presented as a percentage of the untreated population. The results show that MGBG treatment
inhibited differentiation of monocytes into both M1 and M2 macrophage phenotypes. MGBG
Fig 4. MGBG showed greater inhibition on CD16 expression in monocytes than that in differentiated
macrophages. Monocytes were isolated from PBMCs using CD14 microbeads. Cells were cultured for 1, 3, and 6 days
with various concentrations of MGBG, and collected for CD16 expression measurement using flow cytometry. MGBG
showed greater inhibitory effect on CD 16 expression in 1 and 3 day monocytes than that in differentiated
macrophages. The average CD16 geometric mean fluorescence was measured at 108, 448, and 249 for 1, 3, and 6 day
untreated cells, respectively. n = 4, means and SEM.
https://doi.org/10.1371/journal.pone.0192680.g004
MGBG regulates OPN expression in monocytes
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Fig 5. SPM reversed the MGBG inhibitory effects on sOPN and CD16 expression in monocytes. PBMCs were cultured for 3 days
with or without treatment. Cells were cultured with 10 μM MGBG and various concentrations of SPM. (A). MGBG significantly
decreased sOPN; SPM reversed the MGBG inhibitory effects on sOPN. The average sOPN level of 3 day untreated and 10 μM MGBG
treated cells was 30 and 2 ng/ml, respectively. n = 6, means and SEM. (B). MGBG inhibited monocyte CD16 expression; SPM
reversed the MGBG inhibitory effects on CD16 expression. Cultured PBMCs were double stained with CD14 and CD16 antibodies
for flow cytometry analysis. The average CD16 geometric mean in untreated and MGBG treated CD14+ monocytes were measured
at 510 and 249, respectively. n = 3, means and SEM. Data was presented as a percentage of inhibition of MGMG treatment only.
https://doi.org/10.1371/journal.pone.0192680.g005
Fig 6. MGBG inhibited polarization of monocytes into M1 and M2 macrophages. Isolated human monocytes were
cultured to differentiate and induced to M1 or M2 macrophages using 50 ng/ml INF-γ and 1 μg/ml LPS or 50 ng/ml
IL4 for 5–6 days with or without 0.4 μM MGBG. Cells were cultured and evaluated by flow cytometry at day 5 or 6.
Mono: Baseline expression of cell surface markers in 4 hr cultured monocytes (% of all monocytes); Mac: Cultured in
normal media -/+ 0.4 μM MGBG; M1: Cultured in M1 polarizing media -/+ 0.4 μM MGBG; M2: Cultured in M2
polarizing media -/+ 0.4 μM MGBG. MGBG inhibited monocyte differentiation in both M1 and M2 macrophages.
n = 2.
https://doi.org/10.1371/journal.pone.0192680.g006
MGBG regulates OPN expression in monocytes
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inhibited monocyte expression of CD64, a characteristic marker of M1 macrophages. In paral-
lel cultures for M2 induction, MGBG interfered with the initiation of expression of M2 marker
CD200R as well. In contrast to the effects on differentiation exhibited by MGBG, there was no
significant effect on regulating expression of the pan monocyte/macrophage marker CD14 in
parallel cultures.
Discussion
Macrophage activation plays a pivotal role in chronic inflammation which is fundamental in
the etiology of many diseases. Regulating the activation of macrophages could lead to a means
of prevention or treatment of these diseases. MGBG, a compound that inhibits polyamine bio-
synthesis, inhibits TNF-induced macrophage activation [54], HIV proviral DNA integration
in macrophages [58], and OPN gene expression in PBMCs [59]. In this study, we further inves-
tigated the drug’s effects on monocyte differentiation and OPN production.
Previous studies have shown that MGBG is selectively taken up by monocytes and macro-
phages [58]. These cells are also the main source of OPN in non-stimulated PBMC cultures
(S11 Fig). Thus, the effects of MGBG on OPN expression in PBMC preparations most likely
represent the effects of the drug on monocytes and macrophages. Studies carried out in puri-
fied monocytes further confirmed that MGBG’s inhibitory effect on OPN occurs at the RNA
transcription level (Fig 1). This inhibitory effect was accompanied by the loss of secretory
OPN in culture supernatants. This effect was restricted to sOPN since iOPN levels were largely
unaffected in these short term assays. Furthermore, MGBG’s inhibitory effect on sOPN pro-
duction was more pronounced in longer term of exposures (Fig 2A). This inhibitory effect was
reversed by the addition of SPM. In Fig 5A, 1 μM SPM was effective in attenuating the inhibi-
tory effect of 10 μM MGBG on sOPN production. SPM treatment alone showed no significant
effects on monocyte OPN expression. MGBG is taken up by monocytes through the polyamine
transporter in a temperature dependent manner, and SPM acts as a competitor of MGBG
uptake [58]. This experiment confirms our conclusion that the MGBG activity is dependent
on the polyamine transporter, as previously described for the anti-HIV activities of MGBG.
Freshly isolated blood CD14+CD16- monocytes differentiate into CD14+CD16+ mono-
cytes during in vitro culture [15, 16] Fig 2A). Pro-inflammatory CD14+CD16+ monocytes
play an essential role in infection and inflammation [20–25]. In this study, MGBG treatment
of cultured monocytes resulted in a dose-dependent inhibition of CD16 expression (Fig 3B).
This inhibitory effect is reversed by the addition of SPM (Fig 5B), suggesting that polyamine
biosynthesis may be required for the conversion of CD14+CD16- monocytes into CD14+16
+ monocytes. In addition, MGBG treatment decreased production of pro-inflammatory cyto-
kines such as TNF-α produced by monocytes (S12 Fig). Thus, MGBG may attenuate the
inflammatory response through regulation of monocyte differentiation. In this study we also
found that MGBG interferes with monocyte DNA synthesis during differentiation. The BrdU
incorporation experiment suggests that monocyte differentiation is accompanied by DNA
synthesis and that MGBG interferes with this process. Although the role, if any, that DNA syn-
thesis plays in monocyte differentiation remains to be clarified, the observation that these
activities are inhibited by MGBG at similar doses and time of exposure suggests a linkage
between these processes.
OPN is recognized as a Th1 pro-inflammatory cytokine and a major chemoattractant pro-
tein for monocyte migration [32, 33]. It has been reported that OPN is involved in macrophage
survival and differentiation, and that OPN expression is required for maintenance of the mac-
rophage differentiated phenotype [64]. OPN promotes the survival of activated and HIV-1
infected macrophages and thereby may promote the pathogenesis of HAD [65]. Therefore,
MGBG regulates OPN expression in monocytes
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MGBG mediated inhibition of OPN expression could interfere with the accumulation of mac-
rophages generated from monocytes, as well as result in loss of pathogenic macrophages within
diseased tissues. In HAD, this could lead to loss of HIV-1 infected macrophages, and perhaps
reverse this aspect of the disease.
OPN has also been implicated in pathogenesis of obesity. It has been identified as a major
player in monocyte chemotaxis, differentiation and local adipose tissue macrophage prolifera-
tion in obesity [66]. OPN promotes macrophage polarization towards M2 phenotype in exper-
imental obesity [67]. The dose-dependent inhibitory effects of MGBG on OPN production,
monocyte differentiation and BrdU uptake shown in this study imply a linkage among these
activities. The effects of MGBG on monocyte differentiation and proliferation could be the
result of a direct effect of the drug on OPN levels. MGBG also inhibits polyamine biosynthesis;
however a specific role of polyamines, if any, in these processes remains to be defined. The
effects of MGBG and OPN on monocyte/macrophage function deserve further study. The data
presented here suggests that by interfering with OPN production, as well as monocyte differ-
entiation and proliferation, MGBG might be useful for inhibiting macrophage driven pro-
cesses in the pathogenesis of obesity.
The expression of OPN by mature macrophages is important in aspects of wound healing
[28]; therefore it was essential to test whether the OPN regulatory effect of MGBG extended
beyond the level of monocytes to mature macrophages. In experiments wherein monocyte cul-
tures were exposed to MGBG at time points after initiation of culture, we found that the
MGBG regulatory effect on OPN expression diminished after monocytes differentiated into
mature macrophages (Fig 2B). Although MGBG efficiently enters both monocytes and macro-
phages [58], it functions more effectively at regulating OPN and CD16 expression in mono-
cytes. This could be due to higher drug concentrations accumulating in the monocytes as
compared to macrophages [58]. The relative monocyte-specific effects of MGBG allow the tar-
geting of a narrow window of time in the monocyte differentiation process rather than mediat-
ing a global macrophage effect. The effect of MGBG on wound healing deserves extensive
investigation.
The effect of MGBG on monocyte activation and polarization was further examined in
studies where monocyte cultures were induced to become M1 or M2 macrophages compared
with normal culture conditions. MGBG inhibited expression of differentiation markers of
both M1 (CD64) and M2 macrophages (CD200R). However, expression of CD14, the pan
monocyte/macrophage marker, was not significantly affected by the drug treatment. There-
fore, MGBG appears to be a general inhibitor of monocyte differentiation and interfere with
the initiation of macrophage polarization.
Inflammation plays an essential role in the pathogenesis of HIV-associated neurocognitive
disorders (HAND). This is in part driven by HIV-infected macrophages with ongoing migra-
tion of activated monocytes into the central nervous system in the presence of elevated levels
of OPN expression [68–70]. MGBG was tested for in vivo effects on disease activity in an ani-
mal model of AIDS dementia. In a simian immunodeficiency virus encephalopathy (SIVE)
model wherein OPN expression in brain macrophages contributes to AIDS dementia patho-
genesis, MGBG inhibits expression of OPN and SIV p28 expression within the brain, and
appears moderately effective in preventing the macaques from developing SIVE [71]. MGBG
also reduces monocyte activation, the dorsal root ganglia pathology, and inflammation in the
SIVE model [72]. In this model, SIV infected macaques also developed myocarditis and early
atherosclerosis, processes independent of the presence of infected cells within diseased tissues.
MGBG inhibits this systemic manifestation of SIV infection [73]. Therefore, MGBG can
apparently interfere with macrophage infection and secondary disease sequelae (SIVE) as well
as interfere with disease pathogenesis associated with monocytic activation and migration
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contributing to inflammatory complications of SIV infection. These studies also demonstrated
that MGBG given orally was non-toxic at the doses employed. The tissue levels of MGBG
including those in the brain exceeded that required to cause the effects on monocyte differenti-
ation demonstrated in the current study.
In this study we show that MGBG interferes with OPN expression in monocytes and inhib-
its monocyte differentiation into both M1 and M2 macrophages. The unique characteristics of
MGBG, such as monocyte/macrophage specificity, the ability to cross blood-brain barrier, oral
bioavailability, and without significant in vivo toxicity, make it an interesting candidate for
drug development targeting diseases associated with enhanced macrophage activation and
chronic inflammation.
Supporting information
S1 Fig. Gating strategy for FACS analysis. Freshly isolated or cultured human monocytes
were stained with antibody or matching isotypes. For gating, cell debris was first excluded by
forward and side scatters. In the FL1/3 or FL2/3 plots, CD14- cells were excluded based on the
isotype staining. CD16 or iOPN geometric mean was obtained from the gated CD14+ cells.
When cell percentage was used for calculation, cells were gated using quadrants.
(TIF)
S2 Fig. FACS data for iOPN shown in Fig 1.
(TIF)
S3 Fig. FACS data for CD16 shown in Fig 3A.
(TIF)
S4 Fig. FACS data for CD16 shown in Fig 3B.
(TIF)
S5 Fig. FACS data for BrdU incorporation shown in Fig 3C.
(TIF)
S6 Fig. FACS data for 1D CD16 shown in Fig 4.
(TIF)
S7 Fig. FACS data for 3D CD16 shown in Fig 4.
(TIF)
S8 Fig. FACS data for 6D CD16 shown in Fig 4.
(TIF)
S9 Fig. FACS data for Fig 5B.
(TIF)
S10 Fig. FACS data for Fig 6.
(TIF)
S11 Fig. Monocytes are the main source of OPN in PBMC cultures. PBMCs, isolated CD14
+ monocytes, and CD14- cells were cultured for 1, 3, 6 days for sOPN measurement. CD14
+ monocytes/macrophages are the major OPN producing cells in non-stimulated PBMCs.
n = 4, means and SEM.
(TIF)
S12 Fig. MGBG decreased LPS-induced TNF-α in PBMC cultures. PBMCs, isolated CD14
+ monocytes, and CD14- cells were cultured for 1 and 3 days with or without MGBG
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treatment. Cells were treated with 10 ng/ml LPS for 2 hours before culture supernatants being
collected for TNF-α measurement. A. Monocytes are the major source of LPS-induced TNF-α
cytokine in cultured PBMCs. n = 2. B. MGBG treatment decreased LPS-induced TNF-α in
PBMC cultures. n = 2.
(TIF)
S1 Table. P-values for Figs 1–5.
(PDF)
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